Artia Global Partners LP
Artia Global Partners LP reported 48 holdings worth US$542M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Artia Global Partners LP reported 48 holdings worth US$542M as of Jun 30, 2026. Largest: Abivax Sa, Insmed Incorporated and Trevi Therapeutics, Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 48
- Value as reported
- US$542M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Abivax Sa | 516K | US$68.8M | 12.7% |
| Insmed Incorporated | 589K | US$62.8M | 11.6% |
| Trevi Therapeutics, Inc. | 2.21M | US$41.2M | 7.6% |
| Brightspring Health Services, Inc. | 517K | US$36.1M | 6.7% |
| Revolution Medicines, Inc. | 185K | US$34.7M | 6.4% |
| Argenx Se | 29,739 | US$27.6M | 5.1% |
| Travere Therapeutics, Inc. | 339K | US$19.3M | 3.6% |
| Dianthus Therapeutics, Inc. | 163K | US$15.9M | 2.9% |
| Quest Diagnostics Incorporated | 65,122 | US$13.8M | 2.5% |
| Ionis Pharmaceuticals, Inc. | 144K | US$11.4M | 2.1% |
| Eyepoint, Inc. | 767K | US$11M | 2.0% |
| Alumis Inc. | 279K | US$7.84M | 1.4% |
| Viking Therapeutics, Inc. | 181K | US$7.05M | 1.3% |
| Celcuity Inc. | 59,316 | US$6.21M | 1.1% |
| Cytokinetics, Incorporated | 70,700 | US$6.02M | 1.1% |
| Merck & Company, Inc. | 46,700 | US$6M | 1.1% |
| Rapport Therapeutics, Inc. | 139K | US$5.77M | 1.1% |
| Johnson & Johnson | 22,600 | US$5.74M | 1.1% |
| Guardant Health, Inc. | 38,100 | US$5.72M | 1.1% |
| Absci Corporation | 464K | US$5.38M | 0.99% |
| Scholar Rock Holding Corporation | 96,285 | US$5.3M | 0.98% |
| Sionna Therapeutics, Inc. | 120K | US$5.27M | 0.97% |
| Roivant Sciences Ltd. | 130K | US$4.59M | 0.85% |
| Palisade Bio, Inc. | 1.99M | US$4.16M | 0.77% |
| Edgewise Therapeutics, Inc. | 98,800 | US$4.01M | 0.74% |
| Biogen Inc. | 18,437 | US$3.98M | 0.74% |
| Xenon Pharmaceuticals Inc. | 65,000 | US$3.92M | 0.72% |
| Mineralys Therapeutics, Inc. | 138K | US$3.72M | 0.69% |
| Prokidney Corp. | 1.81M | US$3.69M | 0.68% |
| Enliven Therapeutics, Inc. | 72,100 | US$3.66M | 0.68% |
| Oruka Therapeutics, Inc. | 33,400 | US$3.18M | 0.59% |
| Protagonist Therapeutics, Inc. | 22,951 | US$2.81M | 0.52% |
| United Therapeutics Corporation | 5,000 | US$2.71M | 0.50% |
| Bright Minds Biosciences Inc. | 38,407 | US$2.7M | 0.50% |
| Compass Therapeutics, Inc. | 383K | US$839K | 0.15% |
| Praxis Precision Medicines, Inc. | 2,500 | US$837K | 0.15% |
| Kodiak Sciences Inc | 17,019 | US$663K | 0.12% |
| Tenax Therapeutics, Inc. | 42,080 | US$612K | 0.11% |
| Nuvalent, Inc. | 4,900 | US$605K | 0.11% |
| Pepgen Inc. | 205K | US$370K | 0.07% |
| Spyre Therapeutics, Inc. | 4,000 | US$355K | 0.07% |
| Bridgebio Pharma, Inc. | 0 | US$0 | 0.00% |
| Eli Lilly And Company | 0 | US$0 | 0.00% |
| Soleno Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Terns Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Abbvie Inc. | 0 | US$0 | 0.00% |
| Apogee Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Ascendis Pharma A/s | 0 | US$0 | 0.00% |
| Avalo Therapeutics, Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related